IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immuneering Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $236.79M
- P/E (TTM)
- –
- Dividend yield
- –
Immuneering statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Immuneering | Industry median |
|---|---|---|
| Market Cap | $236.79M | $166.30M |
| Enterprise Value | $195.47M | $88.19M |
| PB Ratio | 1.24 | 2.03 |
| P/TBV Ratio | 1.29 | 2.29 |
Income (trailing twelve months)
| Measure | Immuneering | Industry median |
|---|---|---|
| Operating Income | -$63.47M | -$21.40M |
| Net Income | -$57.28M | -$22.46M |
| EBITDA | -$63.15M | -$16.91M |
| EPS (Diluted) | -$1.04 | -$0.83 |
Returns
| Measure | Immuneering | Industry median |
|---|---|---|
| Return on Equity (ROE) | -52.1% | -53.2% |
| Return on Assets (ROA) | -47.3% | -40.9% |
| Return on Invested Capital (ROIC) | -66.0% | -32.4% |
| Return on Capital Employed (ROCE) | -32.7% | -38.1% |
Balance sheet
| Measure | Immuneering | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $41.32M | $61.43M |
| Net Cash (Debt) | $41.32M | $15.35M |
| Net Cash Per Share | $0.64 | $0.66 |
| Equity (Book Value) | $190.74M | $49.09M |
| Book Value Per Share | $2.95 | $1.37 |
| Tangible Book Value | $183.74M | $23.52M |
| Working Capital | $149.88M | $76.81M |
Financial position
| Measure | Immuneering | Industry median |
|---|---|---|
| Current Ratio | 19.47 | 3.34 |
| Quick Ratio | 5.09 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Immuneering | Industry median |
|---|---|---|
| Operating Cash Flow | -$56.75M | -$12.35M |
| Capital Expenditures | -$238.46K | -$1.08M |
| Free Cash Flow | -$56.99M | -$20.22M |
| FCF Per Share | -$0.88 | -$0.42 |
Efficiency
| Measure | Immuneering | Industry median |
|---|---|---|
| Profits Per Employee | -$1.08M | -$703.34K |
| Employee Count | 53 | 74 |
Dividends and yields
| Measure | Immuneering | Industry median |
|---|---|---|
| Earnings Yield | -24.2% | -23.3% |
| FCF Yield | -24.1% | -8.72% |
Shares
| Measure | Immuneering | Industry median |
|---|---|---|
| Shares Outstanding | 64,697,400 | 58,127,000 |
| Shares Change (YoY) | 76.6% | 10.9% |
| Float | 57,187,600 | 49,136,700 |
| Shares Held by Insiders | 11.6% | 11.6% |
| Shares Held by Institutions | 53.3% | 59.4% |
Scores
| Measure | Immuneering | Industry median |
|---|---|---|
| Altman Z-Score | 10.25 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Immuneering's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.